India’s Directorate General of Foreign Trade on April 17 issued a delayed order naming 15 banks authorised by the Reserve Bank of India to import gold and silver from April 1, 2026 to March 31, 2029, ending a hold-up that forced banks to halt new bullion purchases. The list, which did not explain the delay, allows major lenders including State Bank of India, HDFC Bank and Bank of India to import both metals; Union Bank of India and Sberbank are permitted to import only gold. Traders had reported more than 5 metric tonnes of gold and about 8 tonnes of silver stuck at customs while awaiting clearance, and banks had paused fresh overseas orders. The disruption coincided with preparations for the Akshaya Tritiya festival and came amid wider government efforts to manage the trade deficit as oil and other import costs rise. Market sources said inventories had drawn down and jewellery demand, ETF flows and premiums could be affected until customs clearances resume.

A federal judge in Sacramento issued a preliminary injunction on April 17-18, 2026, barring Nexstar Media Group from integrating recently acquired Tegna stations while antitrust litigation proceeds. Chief U.S. District Judge Troy L. Nunley found plaintiffs — DirecTV and a coalition of eight state attorneys general led by California’s Rob Bonta and New York’s Letitia James — likely to succeed on claims that the roughly $6.2 billion deal would substantially lessen competition in local television markets. The order does not unwind the March 19 closing, which followed approvals and limited waivers from the Federal Communications Commission and the Justice Department, but requires Nexstar to maintain Tegna as a separate, economically viable business unit and refrain from consolidating operations. Plaintiffs argue the tie-up, which gives Nexstar control of about 265 stations reaching roughly 80% of U.S. households, would raise retransmission fees, threaten local newsrooms and enable leverage over pay-TV providers (including potential blackouts of NFL games). Nexstar said it will appeal to the Ninth Circuit. The injunction takes effect April 21 and the case will proceed to trial, where defeat could force an unwind of the transaction.

Autoliv reported first-quarter 2026 results on April 17 that beat analysts’ forecasts, sending shares up about 9–10%. Net sales rose 6.8% year‑on‑year to $2.75 billion, helped by a strong March and favourable currency translation. Adjusted operating profit was $245 million (versus $255 million a year earlier) and an adjusted operating margin of 8.9%, topping analyst polls; adjusted EPS was $2.05. Operating cash flow was negative $76 million, reflecting a working‑capital build tied to end‑of‑quarter sales, and net leverage stood at about 1.3x. Management reiterated full‑year guidance of an adjusted operating margin of 10.5–11% and roughly $1.2 billion in operating cash flow, paused share repurchases for the quarter but retained a $2.5 billion authorization, and continued a $0.87 quarterly dividend. Company commentary highlighted outperformance in Asia — notably China and India — and product expansion including motorcycle airbag systems. Analysts and data providers reacted positively, though some flagged cash‑flow timing, tariff effects and insider selling as near‑term watchpoints.

Fifth Third Bancorp reported robust first-quarter results on April 17, 2026, driven by higher net interest income and early benefits from its acquisition of Comerica. Adjusted net income available to common shareholders rose to about $731 million for the quarter ended March 31, versus $502 million a year earlier. Net interest income climbed more than 34% to roughly $1.93 billion and net interest margin expanded by about 27 basis points. Average portfolio loans and leases increased to about $157.6 billion while capital markets fees rose sharply (to $134 million), reflecting stronger underwriting and risk-management activity. Management said the Comerica transaction, which closed on Feb. 1, is integrating on schedule and is already contributing to margin and tangible book value gains. The bank also reported limited exposure to private credit and said deposit costs have eased following Federal Reserve rate cuts in late 2025. Results were accompanied by guidance and targets tied to integration synergies and a planned systems conversion over the summer, with management flagging execution risks around technology migration and customer transitions.

Spirit Airlines has privately asked the Trump administration for hundreds of millions of dollars in emergency funding as a surge in jet fuel prices imperils its restructuring and raises the prospect of liquidation, multiple reports said on April 16-18, 2026. The Department of Transportation has requested a meeting with executives from several low-cost carriers, including Spirit, with a scheduled briefing with Transportation Secretary Sean Duffy next week. Spirit, which filed for Chapter 11 twice in less than a year and plans to shrink its fleet to about 76-80 aircraft by Q3 2026, built its turnaround on much lower fuel assumptions (about $2.24 per gallon). By mid-April jet fuel was trading around $4.24 per gallon, a shock J.P. Morgan estimates could add roughly $360 million in costs and push operating margins deep into negative territory. Creditors, including Citibank, have objected to the carrier’s exit plan, warning of defaults and potential repossession of collateral. Spirit reported limited unrestricted cash at end-2025 and faces contractual cash uses tied to its bankruptcy financing. While an immediate shutdown is not certain, several outlets said liquidation could not be ruled out in the near term.

Kailera Therapeutics raised $625 million in an initial public offering and began trading on Nasdaq on April 17, 2026 under the ticker KLRA. The biotech sold roughly 39.06 million shares at $16 each and the stock opened at $26, a surge of about 62.5% from the offering price. The deal, one of the largest biotech IPOs in recent years, pushed the company’s valuation into the low billions after the first-day pop. Kailera is developing multiple GLP-1–class obesity treatments, including a global Phase 3 injectible GLP-1/GIP candidate and an oral GLP-1 program; key late-stage readouts for the lead program are not expected until 2028. Backers include prominent venture investors such as Bain Capital, Atlas Venture and Arch Venture Partners. The listing underscores strong investor appetite for obesity drugs as established players like Novo Nordisk and Eli Lilly dominate a market projected to reach roughly $150 billion annually by the end of the decade.